MAP2K2 and neoplasm: Indeed, CEBPB and EP300, along with genes related to the Mitogen-Activated Protein Kinase (MAPK) signaling cascade such as MAP3K1, MAP2K2, and MAP3K11 were significantly upregulated in RMC tumor cells following treatment with nivolumab plus ipilimumab, (Fig. 2f).